INIT — Initiator Pharma A/S Share News
0.000.00%
Last trade - 00:00- SEK195.09m
- SEK176.92m
Brief: Initiator Pharma To Fully Prioritize Pudafensine
Brief: Initiator Pharma Reports Q4 Net Revenue Of DKK 0.00
Brief: Initiator Pharma Q4 Operating Loss Widens To DKK 7 Mln
Brief: Initiator Pharma Granted European Patent For Pudafensine in FSD
Brief: Initiator Pharma Q3 Operating Loss At DKK 4.3 Mln
Brief: Initiator Pharma Gets UK CTA Approval For Phase 2a Study
Brief: Initiator Pharma Q2 EBIT Loss Narrows To DKK 3.8 Mln
Brief: Initiator Pharma Says 43.7% Of Rights Issue Subscribed Through Subscription Rights
Brief: Initiator Pharma Updates Timeline For Rights Issue
Brief: Initiator Pharma Resolves On Rights Issue Of SEK 56 Mln
Brief: Initiator Pharma Expands FSD Program To Include Vulvodynia
Brief: Initiator Pharma Q1 Operating Loss At DKK 2.65 Mln
Brief: Initiator Pharma Q4 Operating Loss DKK 2.7 Mln
Brief: Initiator Pharma Q3 Oper Loss Narrows To DKK 3.2 Mln
Brief: Initiator Pharma Completes Share Buyback
Brief: Initiator Pharma Q2 Operating Loss Narrows To DKK 5 Mln
Brief: Initiator Pharma Jan-March EBIT Loss Narrows To DKK 3.6 Mln
Brief: Initiator Pharma Q4 Operating Loss Narrows To DKK 4.3 Mln
Brief: Initiator Pharma Says Mac Clinical Research Converts Receivable Into Shares